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Trial DesignAcute cardioversion vs a wait-and-see
approach for recent-onset symptomatic atrial
fibrillation in the emergency department:
Rationale and design of the randomized
ACWAS trial
Dudink Elton,MD, a Essers Brigitte,MSc, b HolvoetWouter,MD, a,c Weijs Bob,MD, PhD, a,c Luermans Justin,MD, PhD, a
Ramanna Hemanth, MD, PhD,d Liem Anho, MD, PhD,e van Opstal Jurren, MD, PhD, f Dekker Lukas, MD, PhD, g
van Dijk Vincent, MD, PhD, h Lenderink Timo, MD, PhD, i Kamp Otto, MD, PhD, j Kulker Lennert, MSc, k
Rienstra Michiel, MD, PhD, l Kietselaer Bas, MD, PhD, a Alings Marco, MD, PhD,m Widdershoven Jos, MD, PhD, n
Meeder Joan, MD, PhD, c Prins Martin, MD, PhD, b van Gelder Isabelle, MD, PhD, l and Crijns Harry, MD, PhDa
Maastricht, Venlo, The Hague, Maastricht University Medical Center, Rotterdam, Maastricht, Eindhoven, Nieuwegein,
Enschede, Leiderdorp, Breda, Heerlen, Tilburg, VU University Medical Center, Amsterdam, and University Medical
Center Groningen, Groningen, the NetherlandsBackground Current standard of care for patients with recent-onset atrial fibrillation (AF) in the emergency department
aims at urgent restoration of sinus rhythm, although paroxysmal AF is a condition that resolves spontaneously within 24 hours
in more than 70% of the cases. A wait-and-see approach with rate-control medication only and when needed cardioversion
within 48 hours of onset of symptoms is hypothesized to be noninferior, safe, and cost-effective as compared with current
standard of care and to lead to a higher quality of life.
Design The ACWAS trial (NCT02248753) is an investigator-initiated, randomized, controlled, 2-arm noninferiority trial that
compares a wait-and-see approach to the standard of care. Consenting adults with recent-onset symptomatic AF in the emergency
department without urgent need for cardioversion are eligible for participation. A total of 437 patients will be randomized to either
standard care (pharmacologic or electrical cardioversion) or the wait-and-see approach, consisting of symptom reduction through
rate control medication until spontaneous conversion is achieved, with the possibility of cardioversion within 48 hours after onset of
symptoms. Primary end point is the presence of sinus rhythm on 12-lead electrocardiogram at 4 weeks; main secondary outcomes
are adverse events, total medical and societal costs, quality of life, and cost-effectiveness for 1 year.
Conclusions The ACWAS trial aims at providing evidence for the use of a wait-and-see approach for patients with
recent-onset symptomatic AF in the emergency department. (Am Heart J 2017;183:49-53.)Background and hypothesis
Recent-onset atrial fibrillation (AF) is one of the most
common arrhythmias seen in the emergency department
(ED). Current standard of care for patientswith symptomaticFrom the aDepartment of Cardiology, Maastricht University Medical Center and
Cardiovascular Research Institute Maastricht, Maastricht, the Netherlands, bDepartment
of Clinical Epidemiology and Medical Technology Assessment, Maastricht University
Medical Center, Maastricht, the Netherlands, cDepartment of Cardiology, VieCuri Medical
Center, Venlo, the Netherlands, dDepartment of Cardiology, Haga Teaching Hospital, The
Hague, the Netherlands, eDepartment of Cardiology, Sint Franciscus Hospital, Rotterdam,
the Netherlands, fDepartment of Cardiology, Medisch Spectrum Twente, Enschede, the
Netherlands, gDepartment of Cardiology, Catharina Hospital, Eindhoven, the Netherlands,
hDepartment of Cardiology, St Antonius Hospital, Nieuwegein, the Netherlands,
iDepartment of Cardiology, Zuyderland Medical Center, Heerlen, the Netherlands,
jDepartment of Cardiology, VU University Medical Center, Amsterdam, the Netherlands,
kDepartment of Cardiology, Alrijne Hospital, Leiderdorp, the Netherlands,
lDepartment of Cardiology, University Medical Center Groningen, Groningen, the
Netherlands, mDepartment of Cardiology, Amphia Hospital, Breda, the Netherlands,AF in the ED, according to ESC guidelines, is mainly aimed at
urgent restoration of sinus rhythm (ie, cardioversion).1 This
is usually achieved by pharmacologic cardioversion (PCV),
electrical cardioversion, or a combination of both.and nDepartment of Cardiology, Elisabeth—TweeSteden Hospital, Tilburg
the Netherlands.
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Flowchart of the study design of the ACWAS trial. R, randomization; CT, computed tomography.
50 Dudink et al
American Heart Journal
January 2017Although immediate cardioversion of patients is proven
to be effective in acute restoration of sinus rhythm,2-4 one
could question the need for immediate restoration of
sinus rhythm because AF is a condition that resolves
spontaneously within 24 hours in more than 70% of the
cases.5-7 In addition, it is known that the symptoms of AF
can successfully be alleviated through medication that
lowers the heart rate (rate control medication, such as
β-blockers, calcium antagonists, or digoxin).8 In the long
term, there is no difference in prognosis between
restoration of sinus rhythm (rhythm control) and rate
control strategies.9,10 Lastly, early cardioversion disallows
the physician to critically observe the electroechocardio-
graphic atrial substrate for the arrhythmia,11 the possibility
to achieve adequate rate control, and the natural course of
the AF episode, including spontaneous conversion.
Considering the above, acute cardioversion can be seen
as a form of overtreatment with respect to long-term
restoration of sinus rhythm, and it may not necessarily
influence development of cardiovascular and cerebrovas-
cular events. Furthermore, avoiding cardioversion could
lower costs and prevent procedure-related adverse
effects. This study aims to prove that a wait-and-see
approach (symptom alleviation and delayed cardiover-
sion when necessary) is safe and noninferior on the
presence of sinus rhythm at 4 weeks, when compared
with standard of care (immediate cardioversion), while
leading to lower health care costs and potentially a higher
quality of life (QoL).Trial oversight
The ACWAS trial is an investigator-initiated, multicen-
ter, randomized, prospective 2-arm trial with either acute
cardioversion or a wait-and-see approach for patients
with recent-onset symptomatic AF at the ED. Thirteen
cardiology departments (3 academic and 10 peripheral)
will be participating in this trial. The study was approved
by the institutional review board of the Maastricht
Academic Hospital/Maastricht University, the Nether-
lands. The statistical analyses will be performed by the
investigators together with an independent statistician
who is involved in the preparation, analysis, evaluation,
and presentation of the study data. The ACWAS trial is
registered at ClinicalTrials.gov (NCT02248753) and the
Netherlands Trial Register (NTR4663). A trial oversight is
presented in Figure 1.
Patient selection
All patients at the ED with recent-onset (b36 hours) AF
without signs of myocardial ischemia and hemodynamic
instability are eligible to participate. Patients must be
suitable for both acute cardioversion and the wait-and-see
approach (Table I).Blood sampling
Upon signing of informed consent, additional blood
will be drawn and stored at −80°C for genetic analysis and
Table I. Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• ECG with AF at the ED
• Heart rate N 70 beats/min
• Symptoms most probable due to AF
• Duration of symptoms b36 h
• Age N18 y
• Able andwilling to sign informed consent
• Able and willing to use MyDiagnostick
• Signs of myocardial infarction on ECG
• Hemodynamic instability
o (systolic blood pressure b 100 mm Hg, heart rate N 170 beats/min)
• Presence of ventricular preexcitation syndrome/accessory conduction
pathway
• History of sick sinus syndrome
• History of unexplained syncope
• History of persistent AF
• Acute heart failure
• Deemed unsuitable for participation by attending physician
• Previously enrolled in the ACWAS trial
• Currently enrolled in another clinical trial
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Volume 183future biomarker analysis for biochemical phenotyping of
the atrial substrate and the correlation with the duration
of the AF attack, and for building prediction models for
spontaneous conversion.
Randomization
Patients will be randomized in a 1:1 fashion to either
acute cardioversion or wait-and-see approach. Random-
ization will be stratified per center, age, sex, and first or
recurrent paroxysm. Randomization group will not be
blinded to attending physician and patient.
Acute cardioversion
Pharmacologic cardioversion
In the acute cardioversion group, first choice of
treatment is immediate PCV through intravenous flecai-
nide (2 mg/kg body weight (150 mg maximum) in 10
minutes). Infusion will be halted in case of conversion to
sinus rhythm, QRS widening (N50%) or adverse effects
(ventricular arrhythmia, atrial flutter with 1: 1 conduc-
tion, hypotension or acute heart failure, AV block, or
allergic reaction).
Electrical cardioversion
In case of contraindications, previous failure of PCV
or current failure of PCV, electrical cardioversion will
be performed under full sedation. A maximum of 3
shocks will be delivered from a biphasic defibrillator in
synchronized mode via self-adhesive electrode pads in
the anterior-apex scheme. Energy will be set at 200, 360,
and 360 J.
Clinically stable patients will be discharged from the
hospital after short (telemetric) observation. Patients will
be admitted in case of complications during or after
cardioversion, that is, ventricular arrhythmia, hemody-
namic instability, or underlying sinus node dysfunction.Wait-and-see approach
Patients in the intervention group will be discharged
from the hospital upon cessation of symptoms through
sufficient rate control (heart rate b 100 beats/min). Rate
control is achieved through the use of intravenous
metoprolol (bolus of 5 mg intravenous, repeated up to
3 times with 5 minutes in between), intravenous
verapamil (5-10 mg in 2 minutes, repeated up to 3 times
with 15minutes in between) or, in case of contraindications
for both, intravenous digoxin (0.5-1 mg). Upon discharge,
the drug is continued orally. Patients will be asked to carry a
Holter device to register exact time of conversion until the
visit to the outpatient clinic or ED, which is planned as close
as possible to 48 hours after onset of symptoms, yet allowing
enough time to perform cardioversion within 48 hours after
onset of symptoms. This ensures that a paroxysmwill always
terminate within 48 hours. During this visit, a 12-lead
electrocardiogram (ECG) will be recorded. In case of
continuing presence of AF, cardioversion as described
above will be attempted.
Anticoagulation and medication
at discharge
All patients will receive CHA2DS2-VASc–guided antic-
oagulation therapy as indicated by current guidelines.1,12
First-time AF patients will be initiated on oral anticoag-
ulant therapy during the index visit. The paroxysm of AF in
both arms of the study will always terminate within 48
hours, either spontaneously or by cardioversion, which is
within the safety margin for anticoagulation-naïve patients.
Upondischarge, inpatients inboth arms, theneed to initiate
or intensifyoral rateor rhythmcontrol drugswill beevaluated.
Follow-up
Upon conversion to sinus rhythm, patients in both
groups will be asked to use a MyDiagnostick, 3 times daily
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January 2017or whenever symptomatic, to determine heart rhythm,
until the next outpatient visit at 4 weeks after the index
visit. This validated devicewill be used tomonitor (time to)
recurrence of AF, and, in that case, AF burden.13
In case of recurrent AF paroxysm during follow-up, either
detected by the MyDiagnostick or through patient symp-
toms, patients will be treated according to the treatment
group to which they have been randomized. Patients in the
intervention groupwill be treated according to the results of
the rate control treatment during the index visit: in case of
early spontaneous conversion using rate control drugs only,
extra rate controlmedication is to be taken at home. Patients
in the control group, or patients who failed to convert
spontaneously,will undergo acute cardioversion.All patients
can contact or visit the ED at any time.
Except for treatment in case of a recurrent paroxysm,
treatment will not deviate from the current standard of
care according to local protocols and is not influenced by
study protocol. Patients will be scheduled for a computed
tomographic angiogram and cardiac ultrasound, if
standard of care according to local hospital protocols.
All patients will visit a cardiologist at the outpatient clinic
after 4 weeks, where a 12-lead ECG will be recorded. The
presence of sinus rhythm on this ECG is the primary
outcome measure. Atrial fibrillation–related complaints
will be recorded and standard physical examination will
be performed. The treating cardiologist will initiate or
continue standard treatment of AF, which will not be
specified by study protocols.
Patients will be asked to fill out questionnaires at 4 time
points: baseline and 1, 6, and 12 months after inclusion,
either through Internet survey or via mail. At each time
point, QoL will be measured through Atrial Fibrillation
Effect on QualiTy-of-Life14 and 36-item Short-Form Health
Survey15 questionnaires. Furthermore, at each time
point, medical consumption of patients inside and
outside the hospital will be registered using the iMTA
Medical Cost Questionnaire,16 whereas productivity loss
will be measured using the iMTA Productivity Cost
Questionnaire.17. Medical files will be assessed for all
medical events, including major adverse cardiac and
cerebrovascular events, medication use, and the use of
attempts to achieve rhythm control. The patient's general
practitioner will be contacted to check for visits to other
hospitals. Associated documents will be requested.Statistical analysis
Primary end point and sample size calculation
The primary end point is the presence of sinus rhythm
on the ECG at 4 weeks after the index visit. This is based
on the pathophysiological principle that AF begets AF,18
from which it may be concluded that not terminating a
paroxysm of AF may lead to progression toward more
frequent and longer paroxysms, potentially leading to
persistent AF. It is thus chosen as a safety end point, toensure that the wait-and-see approach does not lead to
higher rates of AF progression. There is no reason to
assume that there would be a difference in rates of
adverse events between the 2 groups.
Sinus rhythm on the ECG at 4 weeks after the index visit is
expected to be present in 90% of the patients in the control
group.15 A noninferiority margin of 10% is considered
acceptable, given the natural variation in the presence of
sinus rhythm, the generally low impact of the absenceof sinus
rhythm on thewell-being of the patient, and the availability of
good treatment options should treatment be necessary.
With a significance level (α) of .05, a power of 80%,
proportion of 0.9 in the control group, and 0.8 in the
intervention group, and relative sample size of 1.0, 437
patients are required to detect a difference between the
treatment groups (continuity correction applied).16
Interim analysis
The institutional review board judged this study to be a
low-risk trial; hence, we did not install a data safety
monitoring board. However, we decided to plan an
interim analysis at 4 weeks after the inclusion of the 219th
patient (primary end point available in half of the
patients). An independent Interim Analysis Commission,
in which an independent statistician and a cardiologist
not involved in the execution of this trial will take place,
will evaluate the interim results of the trial. First, because
of the uncertainty about the actual outcome rate, they
will assess whether the trial is underpowered or over-
powered on the primary end point. To this end, the
Interim Analysis Commission will receive the percentage
of patients in sinus rhythm for the total study population,
not stratified per randomization arm. Based on this
percentage, the sample size will be recalculated. In a
second phase, they will evaluate the safety of continuing
the trial, by assessing whether the percentage of patients
in sinus rhythm in the experimental group is N10% lower
than in the control group, or a significant difference in
adverse event rate between the treatment arms is found.
Primary analysis
The difference between the groups in the proportion of
patients in sinus rhythm and its 95% CI will be calculated
using the exact method.
Additional analyses
All patient baseline continuous variables will be
expressed as mean ± SD and categorical variables as
percentage values. The primary outcome measure
(presence of sinus rhythm at 4 weeks) will be presented
as number (percentage) of patients. Time-to-recurrence,
number of recurrences, and number of complications
and adverse events will be displayed quantitatively.
Differences between normally distributed continuous
variables will be tested with an independent t test.
Differences between variables with no normal distribution
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variables will be tested with Fisher exact test or χ2 test.
Statistical significance is accepted at the 95% CI (P b .05).
A univariate analysis of the factors that may influence
the spontaneous termination of AF (including age,
gender, cardiovascular history, risk factors, and bio-
markers) will be performed. All covariates showing a
univariate relation (P b .1) with spontaneous termination
will be included in a logistic regression model.
Economic evaluation
The economic evaluationwill be performed from both
health care and societal perspective (productivity loss
or out-of-pocket costs). To address the question
regarding cost-effectiveness, both a cost-effectiveness
analysis and cost-utility analysis from a societal perspec-
tive will be performed.
For the cost-effectiveness analysis, the primary clinical
outcome, sinus rhythm at 4 weeks, will be used. The
incremental costs per quality-adjusted life year will be
calculated using results from the QoL questionnaires
(Atrial Fibrillation Effect on QualiTy-of-Life13 and 36-item
Short-Form Health Survey14). The friction cost method
will be used to calculate the productivity costs according
to Dutch guidelines.19 For the comparison of resource
use, differences between the 2 groups will be analyzed
with bias-corrected bootstrap analysis, as most volumes of
resource use follow a skewed distribution. In addition,
bootstrap analysis will also be used to quantify the
uncertainty surrounding the incremental cost-effectiveness
ratio. Results of this analysis will be presented in
cost-effectiveness planes and acceptability curves. Accord-
ing to the International Society for Pharmacoeconomics and
Outcomes Research task force principles, budget impact
analysis will be performed next to the economic evaluation.
Conclusion
Summary
The ACWAS study will provide results that can guide
the treatment of recent-onset symptomatic AF in the ED.
It will show whether a wait-and-see approach compared
with acute cardioversion is noninferior, safe, and
cost-effective. In that case, the wait-and-see approach
would be a worthy alternative to acute cardioversion.
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